好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Urgent Caesarean Section Followed by Tumor Resection for Pregnancy-related Rapid Growth of WHO Grade 1 Pilocytic Astrocytoma
Neuro-oncology
P4 - Poster Session 4 (11:45 AM-12:45 PM)
5-021

We describe multidisciplinary management of a pregnant woman with presumed hormone related, WHO grade 1 juvenile pilocytic astrocytoma (JPA) growth.

JPA typically occurs before age 20 years, equally among genders, and in cerebellum. JPA-associated BRAF alterations include 10-15% BRAF/V600E mutations and 60-80% BRAF/KIAA1549 fusions. Lack of female predominance argues against estrogen sensitivity as seen with meningiomas or diffuse gliomas. JPA molecular analysis identified microRNAs target MAPK and NF-κB pathways, while estrogen receptor inhibited. 

Case Report

A 31-year-old G2P1 woman with JPA presented emergently with headache, lethargy, aphasia, hemiparesis, and increased intracranial pressure. Diagnosed at age 25 years via biopsy with thermal ablation of an inoperable2.8x2.3x2.3cm left thalamocapsular mass, she enrolled on a MEK inhibitor trial for confirmed BRAF/KIAA1549 fusion, discontinued after 4 days due to intratumoral hemorrhage. While minimal growth to 2.8x2.5x2.2cm was noted at 10EGA, noncontrast brain MRI by 30EGA revealed growth to >4cm3, edema, obstructive hydrocephalus, and transependymal edema. After corticosteroids for fetal lung maturation, emergent C-section delivered a 3lb/11oz baby at EGA 312/7, safely discharged after NICU monitoring.

After minimal improvement on high-dose dexamethasone, left parietal craniotomy at 5 days postpartum resulted in subtotal tumor resection. Two days later, she required emergent craniotomy for intraparenchymal hemorrhage, resulting in gross total resection. Pathology confirmed WHO grade 1 JPA, notably negative for estrogen/progesterone receptors. Postoperative significant mixed aphasia and right hemiparesis improved with rehabilitation. No radiation advised after serial MRIs at 3-6 months postpartum confirmed no residual tumor.

Noncontrast MRI with max 3T magnet is safe and ideal imaging during pregnancy as CT exposes fetuses to radiation, worsened by abdomen shielding due to internal scatter (ACR guidelines). Gadolinium is secreted into amniotic fluid, thus avoided during pregnancy. Gross total resection, even at recurrence after medical or radiotherapy, is curative and thus remains the mainstay intervention for JPA.

Authors/Disclosures
Diana M. Barratt, MD, MPH, FAAN (Diana Barratt, MD, MPH, FAAN)
PRESENTER
Dr. Barratt has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Legally Pink, LLC. Dr. Barratt has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Vlantis Law, LLC. Dr. Barratt has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Traub Lieberman. Dr. Barratt has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Callahan Fusco. Dr. Barratt has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Chane Socarras. Dr. Barratt has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Conroy Simberg. Dr. Barratt has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Crandall & Katt. Dr. Barratt has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Kelley Kronenberg. Dr. Barratt has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Plakas Mannos. Dr. Barratt has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Marshall Denehey. Dr. Barratt has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Pritt & Spano. Dr. Barratt has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Russo Law.
Amina Namrouti, MD Miss Namrouti has nothing to disclose.
Denis Babici, MD Dr. Babici has nothing to disclose.
Michael McDermott (Michael McDermott, Chief Medical Executive, Miami Neuroscience Institute) Michael McDermott has received personal compensation for serving as an employee of National Football League. Michael McDermott has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Zimmer Law. Michael McDermott has or had stock in Deinde Medical.Michael McDermott has or had stock in Zap-X .Michael McDermott has or had stock in Light Helmets. The institution of Michael McDermott has received research support from State of Florida. Michael McDermott has received intellectual property interests from a discovery or technology relating to health care.
Kathleen Thompson No disclosure on file
Zhi-Jian Chen, MD (Miami Cancer Institute/Baptist Health South Florida) Dr. Chen has nothing to disclose.
Yazmin Odia, MD, MS, MBA, FAAN (Miami Cancer Institute, BHSF) Dr. Odia has received personal compensation in the range of $500-$4,999 for serving as a Consultant for PharPoint. Dr. Odia has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for GammaTile. Dr. Odia has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Chimeric, part of Jazz Pharmaceuticals.